Zacks Small-Cap Research

May 23, 2016

Lisa Thompson
312-265-9154
lthompson@zacks.com

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

Finjan Holdings (FNJN-NASDAQ)

FNJN: Zacks Company Report – Proofpoint Settled, Raising Estimates

Based on the average EV to Sales of comparable companies in the IP business we believe FNJN Stock could be worth $6.97 per share next year if it does indeed collect the Blue Coat judgment as expected.

Current Price (05/20/16)	$1.35
Valuation	**$6.97**

UPDATE

Finjan is positioned to grow not only by pursuing IP licensing, but also by penetrating cybersecurity consulting services, and investing in new IP via R&D and in cybersecurity startups. Its new consulting business is having slow start. The company just settled with Proofpoint for $10.9 million and we are hopeful of more settlements and/or licensing deals this year. In 2017 we expect it to collect over $40 million from Blue Coat if the ruling is upheld on appeal, and for the company to retire its new preferred stock.

SUMMARY DATA

52-Week High	**$2.32**
52-Week Low	**$0.83**
One-Year Return (%)	**-2.9**
Beta	**-0.99**
Average Daily Volume (sh)	**67,501**
Shares Outstanding (mil)	**22.7**
Market Capitalization ($mil)	**$31**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**28**
Insider Ownership (%)	**30**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/M**
Earnings Per Share (%)	**N/M**
Dividend (%)	**N/M**
P/E using TTM EPS	**N/M**
P/E using 2016 Estimate	**N/M**
P/E using 2017 Estimate	**1.6**
Zacks Rank	**N/A**

Risk Level	**High**
Type of Stock	**Small-Growth**
Industry	**Internet-Software**

ZACKS ESTIMATES

Revenue
(in millions of $- Restated)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	0.0 R	0.0 R	5.0 A	0.0 A	5.0 A
2015	0.0 A	0.7 A	0.0 A	$4.0 A	4.7 A
2016	2.3 A	4.5 E	3.2 E	1.0 E	11.2 E
2017					53.9 E

Earnings per Share
(Restated EPS is continuing operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	-$0.08 R	-$0.15 R	$0.03 R	-$0.18 A	-$0.38 A
2015	-$0.19 A	-$0.12 A	-$0.21 A	-$0.05 A	-$0.56 A
2016	-$0.05 A	-$0.02 E	-$0.07 E	-$0.16 E	-$0.27 E
2017					$0.85 E

© Copyright 2016, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

Settlement With Proofpoint Yields $10.9 Million

Finjan reached at $10.9 million settlement with Proofpoint last Friday, before the trial that was scheduled to start June 16, 2016. It will be paid in three installments: $4.3 million to be paid within three days of signing, $3.3 million on or before January 4, 2017, and $3.3 million on or before January 3, 2018. We have adjusted our model accordingly, raising revenues for Q2 2016 and the 2016 year. We had thought a license would have yielded $13 million and at $10.9 million we were in the ballpark. We are now at an estimate of $11.2 million in revenues and a loss of $0.27 for the year. For 2017 we are at $54 million and EPS of $0.85 per share in earnings. Between this and the equity raised from temporary preferred stock, the company is set for cash for the next two years.

Temporary Preferred Equity Issued

Last week Finjan also inked a preferred stock deal sold to investors led by Halcyon Long Recovery Durations. In return for $10.2 million in cash, it has offered to repay a minimum of $15.2 million and a maximum of $28 million depending on timing. Its repayments occur in accordance with the wishes of the buyer or the seller. The company agreed to pay 20% of any licensing revenue that is booked and 50% of any court awards and settlements to retire this stock as the buyer requests. The schedule for what Finjan owes to redeem its preferred in this arrangement is as follows:

- From May 12, 2016 to August 10, 2016 (the 90 anniversary of the date of Issuance), 1.5 times or $15,300,000.
- From August 10, 2016 to the 360 day anniversary of the Date of Issuance (August 5, 2017), 1.65 times or $16,830,000.
- From August 5, 2017 to the August 1, 2018, 1.75 times or $17,850,000.
- Thereafter, 1.75 times plus 0.1 times for every 90 period following August 1, 2018.

  The maximum paid will be 2.8 times the purchase price or $28,560,000.



The company stated that there will be no effect on the income statement, but doe the uniqueness of this deal, the auditors are still working out the details. So rather than having this decrease in profitability of the company reflected in earnings, it will be reflected in enterprise value as this new debt is taken on and repaid. If the company needs to borrow the full $10.2 million for the next year, the company will have to pay back $16.83 million yielding annual interest rate of 65% on what is behaving somewhat like a zero coupon bond but is being called temporary equity.

Q1 Shows Less Cash Burn Than Expected

Finjan filed its 10Q and showed two items of interest. First it spent far less in Q1 than we had anticipated and thus burned less cash. We believe this is because it had trials pushed off and did not spend on outside council as much as expected in the quarter. The second item of interest is that CybeRisk only booked $20,000 in revenues, and is ramping at a much slower pace than we expected. This is a difficult business to crack and it may be that we are forecasting too much to fast from this operation. The company reported revenues of $2.32 million: $2 million from Websense, $300,000 from a F-Secure and $20,000 from CybeRisk. Expenses were only $3.5 million versus $4.2 million last year. We believe expenses will trend back up as the company nears trial dates. Reported loss was $1.2 million versus $4.2 million, or -$0.05 versus -$0.19 per share. The company burned through a million in cash versus $3.2 million last year.

Still Awaiting More Possible Settlements

As trial dates approach, and the Patent Office rules on petitions we believe there is also a chance that Sophos could be settled. This **trial is scheduled for September 6, 2016.**

Palo Alto Networks (PANW) may have its stay lifted since the Patent Office ruled on Finjan's patents. It may be more amenable to a licensing deal as this hurdle cleared. Of the 13 petitions for IPR, the PTAB has denied seven petitions in Finjan's favor, partially denied (and partially granted) three petitions, and granted three petitions for review.

'926 Patent: IPR2016-00145: denied
'968 Patent: IPR2016-00149: denied
'968 Patent: IPR2016-00150: denied
'154 Patent: IPR2016-00151: part denied/part granted
'494 Patent: IPR2016-00159: granted
'918 Patent: IPR2016-00164: denied
'780 Patent: IPR2016-00165: denied
'633 Patent: IPR2015-01974: part denied/part granted
'154 Patent: IPR2015-01979: part denied/part granted
'822 Patent: IPR2015-01999: denied
'731 Patent: IPR2015-02000: denied
'408 Patent: IPR2015-02001/IPR201600157 (consolidated): granted on certain claims

FireEye (FEYE) is still stayed pending rulings at PTAB.
Any or all of these may settle as the Proofpoint agreement may prove an impetus for the others.

Q2 2016 Estimate

In Q2 we expect the first payment from Proofpoint amounting to $4.3 million and some revenue booked from CybeRisk. We are reducing our expectations from them to $100,000 in revenues. With the license revenues at 20% gross margin due to payments to outside counsel we expect the company to be closer to breakeven and are looking for non-GAAP EPS loss of $0.02 versus a loss of $0.11 last year.

Q3 2016 Estimate

In Q3 two payments totaling $2.65 million should be received from the mystery licensee. With Sophos is expected to go to trial on September 6, 2016 and a settlement could be reached there between now and then. Sophos has almost twice the revenues of Proofpoint but may not have as much of their products infringing. With no new licensing in this quarter, EPS could be a loss of $0.07.

2016 Year

With the new Proofpoint settlement we are raising revenues for 2016. Using only revenues under contract and some business estimated from CybeRisk, we are now looking for minimal revenue of $11.0 million in 2016. This will increase significantly if further licensing deals/settlements are contracted with any of the parties involved in current litigation, as they are all of a significant size in terms of cybersecurity revenue. At $11.0 million the company could lose $0.30 per share a reduction from our previous estimate of a loss of $0.56 due to the high margin settlement revenues.

RECAP: The Win Against Blue Coat

The big win for Finjan against Blue Coat on August 5, 2015 awarded the company $40 million plus an additional 10% in interest per year. It has increased the value of Finjan significantly as more of its patents have proven to have value and it has more ammunition with which to convince other entities to license its technology. While all six patents were considered valid, the jury decided one, 822, was not applicable to Blue Coat's products. The award breakdown according to papers filed by the jury was as follows, with 844 being the big contributor.

Patent Number	*$ In Millions*	*Filed*
6,154,844	24.00	1997
7,058,822	0	2001
7,647,633	1.67	2005
7,418,731	6.00	2004
6,965,968	7.75	2003
6,804,780	0.11	2000

At any rate litigation with Blue Coat has not ended. Most likely should Blue Coat not settle, it will appeal--a process that could take until the middle of 2017. We have tentative put revenue from this judgment in 2017. In addition there is the new suit against it that encompasses seven patents and addresses new products that have been introduced by Blue Coat since the lawsuit just won was filed in 2013. Specifically the company named certain of Blue Coat's ProxySG Appliances and Software, the ProxyAV Appliances and Software, and WebPulse Services (some of which Blue Coat recently launched) as products that are infringing.

The patents Finjan believes are being infringed upon in this new suit are: 6,154,844; 6,965,968; 7,418,731; 8,079,086; 8,225,408; 8,566,580 and 8,677,494, the last four of which are being asserted against Blue Coat for the first time. According to its press release "Finjan is seeking a jury trial; entry of judgment of direct and indirect infringement of certain claims of each of the asserted patents by Blue Coat; preliminary and permanent injunction against Blue Coat and its officers, among others, from infringing the asserted patents; and damages to be determined by a jury."

The company is still working through the post-trial motions process. There was recently a JMOL hearing. We are awaiting the final district court order on that verdict amount which could include pre and post-judgment interest and recovered fees and expenses in this case.

THE PRESENT COMPANY ENFORCEMENT

Company	Date and Location	Status	Patent numbers
FireEye **($623 million)**	US District Court for the Northern District of California on July 8, 2013	Stayed pending review by PTAB.	**6,804,780**, 8,079,086, 7,975,305, 8,225,408, **7,058,822**, 7,647,633 and 6,154,844
Blue Coat **(est. >$500m)**	US District Court for the Northern District of California on August 28, 2013 US District Court for the Northern District of California on July 16, 2015	**Won $40m judgment. All patents upheld. Only 7,058,822 did not infringe.** Post-trial motions April 28, 2016 Trial date October 30, 2017	6,154,844, **6,804,780**, 6,965,968, **7,058,822**, 7,418,731, and 7,647,633 6,154,844; 6,965,968; 7,418,731; 8,079,086; 8,225,408; 8,566,580; 8,677,494
Proofpoint **($265 million)**	United States District Court for the Northern District of California on December 16, 2013	Settled May 23, 2016 for $10.9 million.	6,154,844, **7,058,822**, 7,613,918, 7,647,633, 7,975,305, 8,079,086, 8,141,154, and 8,225,408
Sophos **($447 million)**	United States District Court for the Northern District of California on March 14, 2014	Pretrial conference August 8, 2015. Trial set Sept. 6, 2016.	6,154,844, **6,804,780**, 7,613,918, 7,613,926, 7,757,289, 8,141,154, 8,566,580, and 8,677,494
Symantec **($6.5 billion)**	United States District Court for the Northern District of California on June 1, 2014	Stay lifted. Proposed schedule submitted.	6,154,844; 7,613,926; 7,756,996; 7,757,289; 7,930,299; 8,015,182; 8,141,154; and 8,677,494
Palo Alto Networks ($1.1 billion)	United States District Court for the Northern District of California on November 4, 2014	Review completed by PTAB. Waiting for stay to be lifted.	**6,804,780**; 6,965,968; **7,058,822**; 7,418,731; 7,613,918; 7,613,926; 7,647,633; 8,141,154; 8,225,408; and 8,677,494

Highlighted patent numbers have been successfully defended in court.

KEY POINTS

- Finjan holds a number of pioneering patents for cybersecurity hardware and software that is relevant to dozens of companies in this space.
- While it has already won a $40 million + judgment against Blue Coat; its biggest opportunity is its litigation with Symantec, a much larger company.
- The company is continuing to file new patents.
- While its patents have already generated > $130M in its licensing and enforcement track record, the company has the potential to continue to reap large licensing revenues from the $21 billion market for cybersecurity software, services and appliance market.
- The technology licensing market in the U.S., once an afterthought, has grown from $33 billion in 1994 to $68 billion in 2002 and is likely over $100 billion today.
- The company's win against Blue Coat proves its patents are still valued and able to be successfully defended and therefore monetized.
- The company's has a market cap of $31 million and could be worth considerably more if it is successful in its licensing pursuits. Estimating revenues of $54 million in 2017 and an industry multiple of 2.6 times sales, the company could be worth as much as $142 million in enterprise value by 2017 if it succeeds in reaching new licensing arrangements.

OVERVIEW

Finjan Holdings is a patent licensing and enforcement firm based in East Palo Alto, California that owns the patents of its predecessor company Finjan Inc., a cybersecurity company that was founded in Israel in 1997. It invented several technologies that are used in current cybersecurity products today. Its three main patent areas:

- Behavior-based methods to detect and prevent threats from the Internet, including email and Web malware
- "Sandboxing" or stripping applications and running potentially malicious code in a safe environment
- Mobile code replacement where the malicious code is stripped and replaced by safe code

VALUATION

Valuation of an IP company, even with a track record, is very difficult. It is even more so with a company like Finjan that has only two court victories, three recent licensing arrangements, and no recurring revenues. We can however look at other IP companies to see how the market values them to make some comparisons. There seems to be two different types of companies in this space, the older stable revenue generating companies like Rambus (RMBS), and the upstarts that trade on events and potential. We can see from the table below, this ranges from Pendrell (PCO) with an negative $36 million enterprise value, to Interdigital (IDCC) with an enterprise value of $1.5 billion and $371 million in sales expected this year. On average, the companies with revenues trade at an average of 2.6X 2016 estimated calendar revenues.

Using a valuation based on enterprise value to sales is easier for unprofitable companies. If Finjan were to generate $54 million in sales in 2017, we could see the market putting a 2.6 times sales multiple on it as shown in the industry average below. Using that and working back to enterprise value per share, we see that given those revenues, Finjan could be worth $6.97 per share by 2017, assuming it achieves our estimated revenue levels in 2016 from licensing and consulting in addition to a settlement received from Blue Coat if the appeal is won.

Company	Ticker	Revenue 2016E	Revenue LTM	EV/ EBITDA	EBIDTA Margin	Enterprise Value / Sales 2016E	Enterprise Value / Sales LTM	Included in Average?	Enterprise Value
Acacia Research	ACTG	$101	$116	7.8x	40%	0.9x	0.8x	y	$89
Interdigital	IDCC	$371	$439	5.9x	58%	4.0x	3.4x	y	$1,490
Inventergy Global	INVT	$9	$5	-4.4x	-100%	2.5x	4.4x	y	$21
Marathon	MARA	$41	$19	-5.9x	-104%	1.3x	2.8x	y	$53
Neonode	NEON	$20	$11	-11.5x	-68%	3.7x	6.5x	y	$72
Network-1	NTIP	NA	$17	3.2x	45%	NA	2.0x	n	$33
Parkervision	PRKR	$10	$11	-1.8x	NM	2.8x	2.6x	y	$28
Pendrell	PCO	$36	$32	-2.6x	29%	-1.0x	-1.1x	n	-$36
Rambus	RMBS	$314	$296	11.3x	34%	3.7x	4.0x	y	$1,170
RPX	RPXC	$338	$288	1.8x	72%	1.1x	1.2x	y	$356
Tessera	TSRA	$263	$253	6.2x	73%	4.2x	4.3x	y	$1,090
Unwired Planet	UPIP	$5	$5	-0.6x	-814%	5.8x	6.4x	n	$29
VirnetX	VHC	$150	$2	-6.9x	NM	1.5x	139.3x	n	$222
FORM Holdings	FH	NA	$25	-1.2x	NM	NM	0.2x	n	$6
Wi-Lan	WILN	$100	$113	2.9x	72%	2.4x	2.1x	y	$239
Average				**1.2x**	**8%**	**2.6x**	**3.2x**		**$461**

	Revenue 2017E	Revenue LTM	EBITDA Margin	Enterprise Value / Sales 2017E	Enterprise Value / Sales LTM	Valuation Range Low	Valuation Range High
Finjan	**$54**	**$7**	**-154%**	**2.6x**	**3.2x**	**$22**	**$143**

Conclusion of Enterprise Value	**$142,678,014**
Market Value	**$158,678,014**
Shares Outstanding	22,778,925
Price per Share	**$6.97**

Another way to look at possible revenues from current activity is to compare the relevant revenues of the various companies involved. We are taking a general guess that 20% of Websense's revenues were affected by Finjan patents which resulted in a licensing fee of $8 million before the Markman Hearing. Proofpoint just yielded $10.9 million right at the pre-trial hearing. Sophos is past Markman and nearing trial so rates should be near Proofpoint rates. Blue Coat went through the full trial and was awarded $40 million. If this is appealed and the company wins on appeal, the sum will be higher as interest and royalties for additional products sold during the litigation process is added on as well as trial expenses. Looking at the rest of the companies we can derive revenues over $280 million adding actuals and for similar licensing at the same stage as Websense. Judgments, of course, may be all over the place.

	2015 Revenues	% Relevant	License	Judgment
Estimated				
FireEye	$623	30%	$18.7	
Proofpoint	265	50%	13.3	
Sophos	447	25%	11.2	
Symantec (2 segments)	4,200	30%	126.0	
Palo Alto Networks	1,100	27%	30.0	
Total potential			199.1	
Actual				
Blue Coat				40.0
Websense	DK	DK	8.0	
Avast Software	DK	DK	3.0	
Undisclosed	DK	DK	3.7	
Proofpoint	265		10.9	
Total actual			14.6	
TOTAL			$240.7	40.0
Plus Blue Coat			**280.7**	

Cybersecurity companies

The new consulting venture, once it starts to generate meaningful revenues, will have different peer comparables where valuations are much higher. For example, FireEye bought Madiant for $1 billion or approximately 7 times sales. Another comparable would be root9b, a company with $141 million enterprise value and a run rate of $38 million, or 3.7 times.

RISKS

- The company has a limited track record with which to set expectations.
- There is no way to predict the timing of lawsuit settlements or licensing agreements, or even the length of a lawsuit.
- As the current company burns cash and has little licensing revenue, it may not generate enough revenues to cover costs and continue operations in the future unless it generates greater income or receives further financing.
- The stock is high risk and is expected to have wide swings in stock price depending on unpredictable events.
- Government is expected to legislate new laws on patent enforcement that could affect the company's ability to monetize its patents as it currently expects.

OWNERSHIP



INCOME STATEMENT

	2015				2016E							
In Thousands	**Q1**	**Q2**	**Q3**	**Q4**	**Q1**	**Q2E**	**Q3E**	**Q4E**	**2014**	**2015**	**2016E**	**2017E**
Websense	$0	$0	$0	$0	$2,000	$0	$0	$0	$4,998	$0	$2,000	$1,000
Other licenses	0	700	0	3,975	300	0	2,650	0	0	4,675	2,950	6,700
CybeRisk Security Solutions	0	0	0	12	20	200	550	1000	0	12	1,770	2,500
Blue Coat				0	0	0	0	0	0	0	0	40,400
Proofpoint						4,300	0	0	0	0	4,300	3,300
Total Revenues	**0**	**700**	**0**	**3,987**	**2,320**	**4,500**	**3,200**	**1,000**	**4,998**	**4,687**	**11,020**	**53,900**
Cost of revenues	0	60	0	754	0	874	39	70	800	814	983	12,680
Gross profit	0	640	0	3,233	2,320	3,626	3,162	930	4,198	3,873	10,038	41,220
Gross Margin		91%		81%	100%	81%	99%	93%	84%	83%	91%	76%
Operating Expenses:												
SG&A	4,205	4,413	4,490	4,254	3,433	4,000	4,600	4,600	13,813	17,362	16,633	20,000
R&D		146	206	39	51	50	50	50	0	391	201	200
Total operating expenses	4,205	4,559	4,696	4,293	3,484	4,050	4,650	4,650	13,813	17,753	16,834	20,200
Operating Income	(4,205)	(3,919)	1,596 (4,696)	(1,060)	(1,164)	(424)	(1,489)	(3,720)	(9,615)	(13,880)	(6,797)	21,020
Other Income												
Gain on settlements	0	0	0	0	0	0	0	0	1,000	0	0	0
Other income	(1)	1,271	0	1	0	0	0	0	0	1,271	0	0
Interest income	9	7	(4)	0	1	0	0	0	90	12	1	100
Total other income	8	1,278	(4)	1	1	0	0	0	1,090	1,283	1	100
Loss before taxes	(4,196)	(2,634)	(4,700)	(1,060)	(1,163)	(424)	(1,489)	(3,720)	(8,525)	(12,597)	(6,796)	21,120
Income taxes	5	0	0	0	-	-	-	-	5	5	5	5
Tax rate					0%	0%	0%	0%	0%	0%	0%	0%
Net Income	(4,201)	(2,634)	(4,700)	(1,060)	(1,163)	(424)	(1,489)	(3,720)	(8,520)	(12,602)	(6,801)	21,115
Net Income Per Share:												
EPS	**($0.19)**	**($0.12)**	**($0.21)**	**($0.05)**	**($0.05)**	($0.02)	**($0.07)**	**($0.16)**	**($0.38)**	**($0.56)**	**($0.30)**	$0.93
Diluted EPS	($0.19)	($0.12)	($0.19)	($0.05)	($0.05)	**($0.02)**	($0.06)	($0.16)	($0.38)	($0.52)	($0.28)	**$0.85**
Avg Shares Outstanding	22,409	22,519	22,562	22,641	22,709	22,757	22,800	22,850	22,404	22,549	22,779	22,624
Diluted Shares	24,315	24,435	24,468	24,560	24,628	24,676	24,719	24,769	24,209	24,444	24,698	24,719
Stock-based Comp	355	100	187	124	142	142	142	142	1448	766	568	568
Non-GAAP Income	(3,846)	(2,534)	(4,513)	(936)	(1,021)	(282)	(1,347)	(3,578)	(7,072)	(11,836)	(6,233)	21,683
Non-GAAP EPS	**($0.17)**	**($0.11)**	**($0.20)**	**($0.04)**	**($0.04)**	**($0.01)**	**($0.06)**	**($0.16)**	**($0.32)**	**($0.52)**	**($0.27)**	**$0.88**

BALANCE SHEET

$ in Thousands	March 31, 2016	Dec. 31, 2015	% Change
Current assets:			
Cash and cash equivalents	$5,062	$6,101	-17%
Accounts receivable, net	-	-	
Prepaid expenses and other current assets	284	322	-12%
Total current assets	5,346	6,423	-17%
Property and equipment, net	243	257	-5%
Investments	2,195	2195	0%
Other long term assets	325	325	0%
Total Assets	8,109	9,200	-12%
Current Liabilities:			
Accounts payable	2,181	2,220	-2%
Accounts payable - related parties	21	17	24%
Accrued expenses	446	450	-1%
Accrued income taxes	9	9	0%
Other current liabilities	0	32	-100%
Total current liabilities	2,657	2,728	-3%
Other non-current liabilities	131	130	1%
Total Liabilities	2,788	2,858	-2%
Stockholders' Equity			
Common stock	2	2	0%
Additional paid-in capital	24,088	23,946	1%
Retained earnings	(18,769)	(17,606)	7%
Total Stockholders' Equity	5,321	6,342	-16%
Total Liabilities & Stockholders' Equity	$8,109	$9,200	-12%
Cash per share	$0.22	$0.27	-17%

CASH FLOW

	Mar. 31, 2016	Dec. 31, 2015	Sept. 30, 2015	Jun. 30, 2015	March 31, 2015	2015 Year
Cash flows from operating activities:						
Net loss	$ (1,163)	$ (1,059)	$ (4,700)	$ (2,641)	$ (4,202)	$ (12,602)
Adjustments to reconcile net loss to net cash used in operating activities:						
Gain on Investment	0	0	0	(1,271)	0	(1,271)
Depreciation and amortization	14	15	9	19	7	50
Loss on disposal of assets	0	34	0	0	0	34
Stock-based compensation	142	124	187	100	355	766
Deferred tax liability	0	0	0	0	0	0
Changes in operating assets and liabilities:						
Accounts receivable	0	0	0	55	1,961	2,016
Inventories	0	0	0	0	0	0
Prepaid expenses and other current assets	38	(81)	(23)	(153)	47	(210)
Other long-term assets	0	(24)	(70)	0	(231)	(325)
Accrued expenses	(4)	13	(361)	(44)	42	(350)
Accounts payable	(39)	72	669	152	(348)	545
Accounts payable - related parties	4	9	0	(10)	(82)	(83)
Other assets	0	97	65	0	0	162
Other liabilities	(31)	0	0	0	0	0
Accrued income taxes	0	1	0	0	8	9
Total Adjustments	(32)	87	280	0	1,397	1,764
Net cash used in operating activities	(1,039)	260	476	(1,152)	(2,443)	1,343
Cash flows from investing activities:						
Purchases of property and equipment	0	(11)	(54)	(133)	(77)	(275)
Proceeds from investment	0	0	0	826	0	826
Purchase of additional investment	0	(250)	(500)	0	0	(750)
Net cash provided by (used in) investing activities	0	(261)	(554)	693	(77)	(199)
Proceeds from exercise of stock options						
Proceeds from exercise of stock options	0	97	29	0	20	54
Net cash provided by financing activities	0	97	29	0	20	54
Net decrease in cash and cash equivalents	(1,039)	96	(49)	(3,100)	(2,500)	1,198
Cash and cash equivalents - beginning	6,101	7,156	11,905	15,005	17,505	
Cash and cash equivalents - ending	15,005	6,101	7,156	11,905	15,005	6,101
Cash paid for income taxes	0	7	0	0	0	7
Non-cash investing and financing activities						
Additional investment held by investee	0	0	0	445	0	445
Purchase of property and equipment in exchange for finance agreement	0	0	0	0	0	0
Operating cash Flow	**(1,007)**	**(886)**	**(4,504)**	**(3,793)**	**(3,840)**	**(13,023)**
Free cash flow	(1,007)	(1,125)	(4,950)	(2,834)	(3,763)	(12,672)

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Lisa Thompson, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.